Ottonello L, Barbera P, Dapino P, Sacchetti C, Dallegri F
First Medical Clinic, Department of Internal Medicine, University of Genova Medical School, Italy.
Clin Exp Immunol. 1997 Oct;110(1):139-43. doi: 10.1046/j.1365-2249.1997.5011400.x.
Human neutrophils, pre-exposed to low concentrations (1-10 ng/ml) of bacterial LPS in the presence of 1% autologous serum, released elastase activity in response to N-formyl-met-leu-phe (fMLP). Both cell incubation with LPS without subsequent fMLP stimulus and fMLP stimulation without prior exposure to LPS failed to promote significant elastase release. Therefore, LPS primes neutrophils for the subsequent release of elastase in response to fMLP. Compared with fMLP, human recombinant C5a had a slight although not significant activity, whereas other chemoattractants such as IL-8, platelet-activating factor and leukotriene B4 were ineffective. The fMLP-induced response of LPS-primed neutrophils was susceptible to suppression by the methane-sulphonanilide anti-inflammatory drug nimesulide and RO 20-1724, which selectively inhibit cAMP-catabolizing phosphodiesterase type IV. This suggests that the elastase release by LPS-primed neutrophils is likely to be controlled by intracellular cAMP, and raises the possibility of limiting pharmacologically the elastase-mediated tissue injury during neutrophilic inflammation.
在1%自体血清存在的情况下,预先暴露于低浓度(1 - 10 ng/ml)细菌脂多糖(LPS)的人中性粒细胞,会因N - 甲酰 - 甲硫氨酰 - 亮氨酰 - 苯丙氨酸(fMLP)而释放弹性蛋白酶活性。单独用LPS孵育细胞而无后续fMLP刺激,以及单独用fMLP刺激而未预先暴露于LPS,均未能促进显著的弹性蛋白酶释放。因此,LPS使中性粒细胞致敏,以便其随后响应fMLP释放弹性蛋白酶。与fMLP相比,人重组C5a虽有轻微但不显著的活性,而其他趋化因子如白细胞介素 - 8、血小板活化因子和白三烯B4则无作用。LPS致敏的中性粒细胞对fMLP诱导的反应易受甲磺酰苯胺类抗炎药尼美舒利和RO 20 - 1724的抑制,这两种药物选择性抑制IV型环磷酸腺苷(cAMP)分解磷酸二酯酶。这表明LPS致敏的中性粒细胞释放弹性蛋白酶可能受细胞内cAMP控制,并增加了在嗜中性粒细胞炎症期间通过药理学方法限制弹性蛋白酶介导的组织损伤的可能性。